Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301890 | 0.83 | ALDH1A1 (0.39) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL20468921 | 0.80 | HTT (0.41) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL23005820 | 0.80 | MAPT (0.34) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL24832197 | 0.79 | HSD17B10 (0.35) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL20456817 | 0.75 | HSD17B10 (0.39) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL14999139 | 0.75 | ALDH1A1 (0.38) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL13458902 | 0.70 | PRKCA (0.32) | — | |
| SCHEMBL13168192 | 0.68 | PRKCA (0.48) | MAPT | |
| SCHEMBL23817270 | 0.67 | MEN1 (0.32) | MAPT | |
| SCHEMBL20473345 | 0.66 | ALDH1A1 (0.43) | MAPTHTTSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885HTT 1544/4885SMN1; SMN2 3983/4885 |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885HTT 1544/4885SMN1; SMN2 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.